An observational study in Cancer Patients, sponsored by Canon Medical Systems, USA. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.
Sponsored by Canon Medical Systems, USA · Observational
Scope Verification of technologies included in the PCD-1000A PET/CT imaging chain.
The study aim is system verification and associated software. Clinical data and clinical feedback will be used for verification.
This is the only study on the registry with Canon Medical Systems, USA as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adult Cancer Patients, 40 years or older, scheduled for a standard-of-care PET/CT scan.
Exclusion Criteria:
Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
Device: PET/CT imaging
Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
Confirm that PCD-1000A PET/CT System is Effective for Its Intended Use
PCD-1000A PET/CT system's performance will be evaluated for oncology PET imaging on cancer patients to verify that the system performs as expected. • Verify that all supported clinical protocols from PET acquisition, reconstruction, to presentation (filtering) perform as expected. Images acquired by PCD-1000A PET/CT will be compared with images acquired during a standard-of-care PET/CT scan by a commercially available PET/CT system just prior to imaging with the PCD-1000A PET/CT System. Image quality evaluation will include assessment of uniformity of the liver, delineation of the lungs, presence of artifacts and using Likert scale.
Time frame: 3 months
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.